USA flag logo/image

An Official Website of the United States Government

SBIR TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUESTOR: ALI ANDALIBI …

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94136
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
N43CM0800027
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
GENESEGUES, INC.
GENESEGUES, INC. 3180 HIGH POINT DRIVE CHASKA, MN 55318-9476
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: SBIR TOPIC 251: DEVELOPMENT OF ANTICANCER AGENTS REQUESTOR: ALI ANDALIBI VEN
Agency: HHS
Contract: N43CM0800027
Award Amount: $185,073.00
 

Abstract:

Metastatic spread of cancer cells is the primary cause of death in cancer patients and developing therapeutic agents that kill primary and disseminated cancer cells is an important topic. The aim of this project is to continue the development of a novel na nocapsule for the delivery of RNAi into tumor cells. Necessary studies to support the filing of an IND will be conducted. Potential off-targeting properties of the nanoencapsulated therapeutic will be investigated in tissue specimens.

Principal Investigator:

Gretchen Unger

Business Contact:


rtu@genesegues.com
Small Business Information at Submission:

GENESEGUES, INC.
GENESEGUES, INC. 3180 HIGH POINT DRIVE CHASKA, MN 55318

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No